FDA Agrees AMT-130 Data Can Support Accelerated Approval in Huntington's Disease, Driving uniQure Re-rating
核心洞察
uniQure was the standout contributor to abrdn Life Sciences Investors (搜索) in Q2 2026, with shares re-rating dramatically following a key FDA regulatory decision.
The FDA agreed that the three-year AMT-130 data set in Huntington's disease (搜索) could serve as the primary basis for a biologics license application under accelerated approval.
The fund's equity portion rose (gross of fees) and outperformed its benchmark, the NASDAQ Biotechnology Index, during the quarter.
uniQure (QURE) was the standout contributor to the abrdn Life Sciences Investors (搜索) fund during the second quarter of 2026, as its shares re-rated dramatically following a pivotal regulatory development. The Food and Drug Administration (搜索) (FDA) agreed that the three-year AMT-130 data set in Huntington's disease (搜索) could serve as the primary basis for a biologics license application under accelerated approval.
The announcement marked a significant milestone for uniQure's gene therapy program in Huntington's disease (搜索), a neurodegenerative condition with substantial unmet medical need. The FDA's agreement positions the AMT-130 clinical data as sufficient to support a regulatory filing through the accelerated approval pathway, a mechanism designed to expedite patient access to therapies addressing serious conditions.
The fund's equity portion rose (gross of fees) and outperformed its benchmark, the NASDAQ Biotechnology Index, during the quarter. uniQure's re-rating was identified as the primary driver of this outperformance, reflecting investor confidence in the regulatory path forward for AMT-130.
Beyond the uniQure position, the invested balance of the fund grew over the quarter, with new capital directed toward earlier-stage science and the new-issue window. This allocation strategy reflects a broader emphasis on innovation across the biotechnology sector, as the fund seeks to capture value from emerging therapeutic platforms and newly public companies.
The commentary was published by Aberdeen Asset Management, which manages the abrdn Life Sciences Investors (搜索) fund. The fund's performance and positioning underscore the market's responsiveness to regulatory clarity in gene therapy development, particularly for rare and neurodegenerative diseases where treatment options remain limited.